- ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
- Several approaches have been taken to enhance immunity against tumors and infectious diseases in humans. These strategies target either the adaptive immune responses, i.e T cells and B cells, or enhance the activity of antigen presenting cells (APC) such as dendritic cells (DC). Dr. Sabado, as the Director of the Vaccine and Cell Therapy Laboratory (VCTL), is involved in developing new approaches to enhance the activity of DC to induce effective immune responses against tumors and infectious diseases in vivo.
See the VCTL website for more information: http://labs.icahn.mssm.edu/sabadolab/
Sabado RL, Bhardwaj N. Dendritic cell immunotherapy. Annals of the New York Academy of Sciences 2013 May; 1284.
Sabado RL, Miller E, Spadaccia M, Vengco I, Hasan F, Bhardwaj N. Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. Journal of visualized experiments : JoVE 2013;(78).
Miller E, Spadaccia M, Sabado R, Chertova E, Bess J, Trubey CM, Holman RM, Salazar A, Lifson J, Bhardwaj N. Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. Vaccine 2015 Jan; 33(2).
Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg JD, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer immunology research 2015 Mar; 3(3).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Sabado did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Hess CSM Building Floor 5 Room 5-110
1470 Madison Avenue
New York, NY 10029